TrialResults - center - Clinical trials results database in cardiology

GAMMA

You are here: Home > Search and browse > Browse treatment 3

Clinical trials of A

Clinical trials of A and meta-analysis are available for the following clinical conditions:

abdominal aortic aneurysm

abdominal aortic aneurysm, endovascular treatment, all type of patients

endovascular vs open repair : Powerlink, 0 - DREAM, 2005 - EVAR trial 1, 2005 - OVER, 2009 -
endovascular repair vs surveillance : EVAR trial 2, 2005 - PIVOTAL (Ouriel), 2010 -

abdominal aortic aneurysm, endovascular treatment, patient with large AAA

endovascular repair vs open repair : DREAM, 2005 - EVAR trial 1, 2005 - OVER, 2009 -
endovascular repair vs surveillance : EVAR trial 2, 2005 -

abdominal aortic aneurysm, endovascular treatment, patients with small AAA

endovascular repair vs surveillance : PIVOTAL (Ouriel), 2010 -

acute coronary syndrome

acute coronary syndrome, cholesterol lowering intervention, early initiation

pitavastatin vs atorvastatin : JAPAN ACS, 2009 -
atorvastatin vs placebo : MIRACL, 2001 - LIPS (sub groups), 2002 - FLORIDA, 2002 - Czech trial, - LAMIL, 1997 - RECIFE, 1999 - PAIS, 2001 - PACT, 2004 - A to Z, 2004 -
atorvastatin vs pravastatin : PROVE IT - TIMI 22, 2004 -
atorvastatin vs usual care : Colivicchi, 2002 - ESTABLISH, 2004 - L-CAD, 2000 - PTT, 2002 -

acute coronary syndrome, myocardial revascularization, all type of patients

routine invasive strategy vs concervative strategy : FRISC 2, 1999 - TACTICS-TIMI 18, 2001 - VINO, 2002 - RITA 3, 2002 - ICTUS, 2007 - TRUCS, 2000 - the Italian Elderly ACS study, 0 - NQWMI (Eisenberg), 2005 - TIMI 3B (PTCA), 1994 - VANQWISH, 1998 - MATE, 1998 -
early invasive management vs delayed invasive strategy : TIMACS, 2009 - ABOARD, 2009 - OPTIMA, 2009 -
early intervention vs early strategy : ISAR-COOL, 2003 -
anistreplase vs placebo : UNASEM, 1992 - TAUSA, 1994 - TIMI 3A, 1993 - Nicklas, 1989 - Gold, 1987 - Williams, 1990 - Freeman, 1992 - van der Brand, 1991 - charbonnier, 1992 - Ardissino, 1990 - TIMI 3B, 1995 - Topol, 1988 -

acute coronary syndrome, antithrombotics, all type of patient

ASA high dose vs ASA low dose : CURRENT - OASIS 7 (ASA), 2010 -
clopidogrel + aspirin vs aspirin : CURE, 2001 - ASPECT-2 (coumadin vs aspirin), 2002 - Cohen (ATACS pilot) (heparin vs asp), 1990 - ATACS (pilot study) warfarin vs aspirin, 1990 -
triflusal vs aspirine : TIM, 2000 -
prasugrel vs clopidogrel : ACAPULCO, - TRILOGY, 0 -
ticagrelor + aspirin vs clopidogrel + aspirin : PLATO, 2009 - DISPERSE-2 (90mg), 2007 -
aspirin vs control : ATACS-pilot, 1990 -
coumadin vs control (on top of aspirin) : ASPECT-2 (coumadin+asp vs asp), 2002 - ATACS (Cohen), 1994 - Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 - ATACS (pilot study) (warfarin vs control), 1990 - ATACS, 1994 - CARS, 1997 - OASIS Pilot (phase 1), 1998 - OASIS Pilot (phase 2), 1998 - OASIS-2 Warfarin Substudy, 2001 - APRICOT-2, 2002 - CHAMP, 2002 - WARIS, 2002 - LoWASA, 2004 - Zibaeenezhad, 2004 -
fondaparinux vs enoxaparin : PENTUA, 2004 - OASIS 5, 2006 -
Bivalirudin vs eptifibatide + heparin : PROTECT-TIMI 30, 2006 -
Argatroban vs heparin : ARGAMI-2, 1998 - HERO, 1997 - BAT (Bittl), 1995 - Klootwijk, 1999 - TRIM, 1997 -
apixaban vs placebo : APPRAISE-1 (2.5 mg bid), 2009 - B0661004, - APPRAISE 2 (CV185-068), - APPRAISE-1 (10mg od), 2009 - VA-pilot, 0 - VA-main, 1983 - RISC, 1990 - ALDUSA-pilot, 0 - Théroux, 1988 - Canadian (Aspirin vs PBO), 1985 - Prandoni, 1991 - Canadian (Aspirin + sulfinpyrazone), 1985 - J-LANCELOT, 2010 - ATLAS ACS-TIMI 46, 2009 - ATLAS ACS TIMI 51, - Canadian (sulfinpyrazone alone), 1985 - Modena, 0 - Plaza, 1993 - Theroux (heparin+aspirin vs PBO), 1988 - RISC (ASP+ heparin vs PBO), 1990 -
dalteparin vs placebo (on top of aspirin) : FRISC (long term), 1996 - FRIC prolonged treatment phase (LWMH vs PBO), 1997 - FRISC (short term), 1996 - Williams, 1997 - Huyhn, 2001 -
enoxaparin vs tinzaparin : EVET, 2005 -
dalteparin vs UFH (on top of aspirin) : FRIC (acute phase LMWH vs UFH), 1997 - ESSENCE, 1997 - TIMI 11 B (short term), 1998 - SYNERGY, 2005 - INTERACT, 2006 - TIMI 11 B (long term), 1998 - FRAXIS (6days), 1998 - FRAXIS (14 days), 1998 -
enoxaparin vs unfractionated heparin : RESCUE, -
otamixaban vs unfractioned heparin : SEPIA-ACS1 TIMI 42, 2009 -

acute coronary syndrome, antithrombotics, unstable angina

enoxaparin vs unfractionated heparin : RESCUE, -

acute coronary syndrome, myocardial revascularization, Elderly patients

routine invasive strategy vs concervative strategy : the Italian Elderly ACS study, 0 - TACTICS-TIMI 18 elderly (sub group), 2001 -

acute coronary syndrome, anticoagulant, All ACS (including AMI)

coumadin vs aspirin : ASPECT-2 (coumadin vs aspirin), 2002 - ATACS (pilot study) warfarin vs aspirin, 1990 -
coumadin vs control (on top of aspirin) : ASPECT-2 (coumadin+asp vs asp), 2002 - ATACS (pilot study) (warfarin vs control), 1990 - ATACS, 1994 - CARS, 1997 - OASIS Pilot (phase 1), 1998 - OASIS Pilot (phase 2), 1998 - OASIS-2 Warfarin Substudy, 2001 - APRICOT-2, 2002 - CHAMP, 2002 - WARIS, 2002 - LoWASA, 2004 - Zibaeenezhad, 2004 -
apixaban vs placebo : APPRAISE-1 (10mg od), 2009 - APPRAISE-1 (2.5 mg bid), 2009 - B0661004, - APPRAISE 2 (CV185-068), - ATLAS ACS-TIMI 46, 2009 - ATLAS ACS TIMI 51, -
warfarin vs placebo (on top of aspirin) : Williams, 1997 - Huyhn, 2001 -
otamixaban vs unfractioned heparin : SEPIA-ACS1 TIMI 42, 2009 -

acute coronary syndrome, anticoagulant, ACS (excluding AMI)

acute coronary syndrome, antiplatelets drug, ACS (excluding AMI)

ASA high dose vs ASA low dose : CURRENT - OASIS 7 (ASA), 2010 -
clopidogrel + aspirin vs aspirin : CURE, 2001 -
prasugrel vs clopidogrel : TRILOGY, 0 -
ticagrelor + aspirin vs clopidogrel + aspirin : PLATO, 2009 - DISPERSE-2 (90mg), 2007 -
aspirin vs control : ATACS-pilot, 1990 -
aspirin vs placebo : VA-pilot, 0 - VA-main, 1983 - RISC, 1990 - ALDUSA-pilot, 0 - Théroux, 1988 - Canadian (Aspirin vs PBO), 1985 - Prandoni, 1991 - Canadian (Aspirin + sulfinpyrazone), 1985 - J-LANCELOT, 2010 - Canadian (sulfinpyrazone alone), 1985 - Modena, 0 - Plaza, 1993 -

acute coronary syndrome, antiplatelets drug, patients with scheduled percutaneous coronary intervention

ASA high dose vs ASA low dose : CURRENT - OASIS 7 (ASA), 2010 -
prasugrel vs clopidogrel : TRITON-TIMI 38, 2007 -

acute coronary syndrome, heparin (UFH or LMWH), all type of patients

UFH, warfarin vs aspirin : Cohen (ATACS pilot) (heparin vs asp), 1990 -
UFH, warfarin vs control (on top of aspirin) : ATACS (Cohen), 1994 - Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 -
UFH + aspirin vs placebo : Theroux (heparin+aspirin vs PBO), 1988 - RISC (ASP+ heparin vs PBO), 1990 -
dalteparin vs placebo (on top of aspirin) : FRISC (long term), 1996 - FRIC prolonged treatment phase (LWMH vs PBO), 1997 - FRISC (short term), 1996 -
enoxaparin vs tinzaparin : EVET, 2005 -
dalteparin vs UFH (on top of aspirin) : FRIC (acute phase LMWH vs UFH), 1997 - ESSENCE, 1997 - TIMI 11 B (short term), 1998 - SYNERGY, 2005 - INTERACT, 2006 - TIMI 11 B (long term), 1998 - FRAXIS (6days), 1998 - FRAXIS (14 days), 1998 -
enoxaparin vs unfractionated heparin : RESCUE, -

acute coronary syndrome, calcium channel blockers, all type of patients

diltiazem vs placebo : Göbel (Dutch study), 1995 - DRS, 1986 -

acute coronary syndrome, fibrinolysis, all type of patients

anistreplase vs placebo : UNASEM, 1992 - TAUSA, 1994 - Nicklas, 1989 - Gold, 1987 - Williams, 1990 - Freeman, 1992 - van der Brand, 1991 - charbonnier, 1992 - Ardissino, 1990 - TIMI 3B, 1995 - Topol, 1988 - TIMI 3A, 1993 -

acute coronary syndrome, anti-anginal drugs, all type of patients

ranolazine vs placebo : MERLIN TIMI 36, 2007 -

acute coronary syndrome, direct factor Xa inhibitors, all type of patients

apixaban vs placebo : APPRAISE-1 (10mg od), 2009 - APPRAISE-1 (2.5 mg bid), 2009 - B0661004, - APPRAISE 2 (CV185-068), - ATLAS ACS-TIMI 46, 2009 - ATLAS ACS TIMI 51, -
otamixaban vs unfractioned heparin : SEPIA-ACS1 TIMI 42, 2009 -

acute coronary syndrome, antiplatelets drug, all type of patients

ASA high dose vs ASA low dose : CURRENT - OASIS 7 (ASA), 2010 -
clopidogrel + aspirin vs aspirin : CURE, 2001 -
prasugrel vs clopidogrel : ACAPULCO, - TRILOGY, 0 -
ticagrelor + aspirin vs clopidogrel + aspirin : PLATO, 2009 - DISPERSE-2 (90mg), 2007 -
aspirin vs control : ATACS-pilot, 1990 -
aspirin vs placebo : VA-pilot, 0 - VA-main, 1983 - RISC, 1990 - ALDUSA-pilot, 0 - Théroux, 1988 - Canadian (Aspirin vs PBO), 1985 - Prandoni, 1991 - Canadian (Aspirin + sulfinpyrazone), 1985 - J-LANCELOT, 2010 - Canadian (sulfinpyrazone alone), 1985 - Modena, 0 - Plaza, 1993 -

acute coronary syndrome, antithrombotics, patients managed with an early invasive strategy

prasugrel vs clopidogrel : TRITON-TIMI 38, 2007 -
bivalirudin vs heparin + GP2b3a inhibitors : ACUITY (biva alone vs hep+aGP2b3a), 2006 - ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 -

acute coronary syndrome, antithrombotics, PCI sub group

bivalirudin vs heparin + GP2b3a inhibitors : ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 - ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 -

acute coronary syndrome, antithrombotics, patients with a recent ACS

apixaban vs placebo : APPRAISE-1 (10mg od), 2009 - APPRAISE-1 (2.5 mg bid), 2009 - B0661004, - APPRAISE 2 (CV185-068), - ATLAS ACS-TIMI 46, 2009 - ATLAS ACS TIMI 51, -

acute coronary syndrome, oxygen therapy, all type of patients

hyperbaric oxygen vs control : Sharifi, 2004 - Swift, 1992 - Thurston, 1973 - Hot MI, 1997 - HOT MI pilot, 1997 - Rawles, 1976 - Ukholkina, 2005 - Wilson, 1997 - AMIHOT II , 2000 - AMIHOT, 2007 -

acute coronary syndrome, New P2Y12 Inhibitors, all type of patients

prasugrel vs clopidogrel : JUMBO-TIMI 26, 2005 - TRITON-TIMI 38, 2007 -
ticagrelor + aspirin vs clopidogrel + aspirin : PLATO, 2009 - DISPERSE-2 (90mg), 2007 -
cangrelor up front vs clopidogrel up front : CHAMPION-PCI, 2009 -
cangrelor up front vs delayed clopidogrel : CHAMPION-PLATFORM, 2009 -

acute myocardial infarction

acute myocardial infarction, antithrombotics, all type of patients

OASIS pilot, 1998 - Horizons, 2008 - any anticoagulant vs aspirin : EPSIM, 1982 - ASPECT-2 (coumadin alone), 2002 - WARIS II (warfarin alone), 2002 -
coumadin vs control (on top of aspirin) : ASPECT-2 (coumadin+ASA vs ASA), 2002 - APRICOT-2, 2002 - Zibaeenezhad, 2004 - WARIS, 1999 - CHAMP, 2002 - CARS (warafrin 3mg), 1997 - LoWASA, 2004 - CARS (warfarin 1mg), 1997 - WARIS II (warfarin+ASA), 2002 -
Argatroban vs heparin : ARGAMI-2, 1998 - HERO, 1997 -
any anticoagulant vs placebo : Sixty Plus reinfarction Study, 1980 - ASPECT, 1994 - FRAMI, 1997 - BIOMACS II, 1999 - AMI-SK, 2002 - MICHELANGELO OASIS-6, 2006 - CREATE, 2005 -
warfarin vs placebo (on top of aspirin) : Williams, 1997 -
Dalteparin vs UFH : ASSENT Plus, 2003 - ASSENT 3, 2001 - HART II, 2001 - Baird, 2002 - ENTIRE-TIMI 2, 2002 - ASSENT 3 Plus, 2003 -

acute myocardial infarction, beta-blockers, immediate beta-blockers

Acebutolol vs placebo : Azancot, 1982 - Van de Werf , 1993 - Yusuf , 1980 - ISIS1 Collaborative Group , 1986 - Yang , 1987 - Heber , 1987 - Snow , 1980 - Thompson , 1979 - Evemy , 1978 - Johansson , 1980 - Macleod , 1980 - Waagstein , 1975 - Norris , 1984 - Peter , 1978 - Pitt , 1976 - Roberts , 1984 - Singh , 1985 - Sloman , 1967 - Balcon , 1966 - Barber , 1976 - Clausen , 1966 - Curtis , 1991 - Dotremont , 1968 - Gupta , 1982 - Gupta , 1984 - Hutton , 1979 - Kahler , 1968 - Ledwich , 1968 - Mueller , 1980 - Multicentre , 1966 - Nigam , 1983 - Norris , 1968 - Norris , 1978 - Lloyd , 1988 - McMurray , 1991 -

acute myocardial infarction, beta-blockers, long term beta-blockers

Darasz , 1995 - Ahlmark , 1974 - Mazur , 1984 - Propranolol vs control : Aronow , 1997 -
Acebutolol vs placebo : APSI, 1990 - Andersen , 1979 - Reynolds , 1972 - Wilhelmsson , 1974 - Yusuf , 1979 - Basu , 1997 - Multicentre international , 1975 - Baber , 1980 - BHAT , 1982 - Hansteen , 1982 - Kaul , 1988 - Wilcox , 1980 - Julian , 1982 -

acute myocardial infarction, myocardial revascularization, facilated PCI

Abciximab vs primary intervention : ERAMI (Mesquita Gabriel), 2003 - REOMOBILE (Arntz), 2003 - Zorman, 2002 - ReoPro-BRIDGING (Gyongyosi), 2004 - Bellandi, 2006 - FINESSE (abciximab-facilitated PCI), 2008 - BRAVE (Kastrati), 2004 - FINESSE (combination-facilitated PCI), 2008 - LIMI (Vermeer), 1999 - PACT (Ross,), 1999 - INTAMI (Zeymer), 2005 - ADVANCE-MI, 2005 - SAMI (O’Neill), 1992 - PRAGUE (Widimisky), 2000 - GRACIA (Fernandez-Aviles,), 2004 - On-Time (van’t Hof), 2004 - TIGER-PA (Lee), 2003 - Cutlip, 2003 -

acute myocardial infarction, myocardial revascularization, all type of patients

duteplase 1, 1993 - ASSENT-1, 1999 - Mathey, 1985 - bolus t-PA vs accelerated t-PA : COBALT, 1997 - InTIME-II, 2000 - inTIME 1, 1998 - Ribichini, 1996 - Garcia, 1997 - GUSTO 2B, 1997 - DANAMI-2, 1997 - C-PORT, 2002 - STAT, 2001 - GUSTO III, 1997 - RAPID-2, 1996 - ASSENT-2, 1999 - TIMI 10B, 1998 -
facilitated stenting vs alteplase : STOPAMI 1, 2000 -
accelerated t-PA vs APSAC : TAPS, 1992 - TIMI 4, 1994 - Bassand, 1991 -
Prehospital thrombolysis vs at hospital thrombolysis : TEAHAT, 1990 - MITI, 1993 - GREAT, 1994 - EMIP, 1993 - Castaigne , 1989 - Roth, 1990 - Schofer, 1990 - Barbash, 1990 - Castaigne, 1987 - Mcneill, 1989 -
primary stenting vs ballon angioplasty : Jaksch, 1998 - GRAMI (Rodriguez), 1998 - Zwolle 5 (Suryapranata), 1998 - stent-PAMI (Grines), 1999 - PASTA (Saito), 1999 - PRISAM (Kawashima), 1999 - STENTIM-2 (Maillard), 2000 - PSSAAMI (Scheller), 2001 - FRESCO, 1998 - CADILLAC abciximab., 2002 - CADILLAC (no abciximab), 2002 - ZWOLLE 6, 2005 - STOPAMI 3, 2004 -
paclitaxel ES vs bare-metal stent : HORIZONS-AMI Stent, 2008 - PASSION, 2006 - HAAMU-STENT, 2006 -
APSAC vs control : APSIM, 1989 - USIM, 1991 -
primary ballon angioplasty vs duteplase : DeWood, 1989 - Gibbons, 1993 - duteplase 2, 1993 - duteplase 3, 1993 -
primary angioplasty vs immediate thrombolysis : MAASTRICHT (Vermeer), 1999 - PRAGUE-1, 2000 - AIR-PAMI, 2002 - CAPTIM, 2002 - DANAMI-2, 2003 - PRAGUE-2, 2003 - STOPAMI 2, 2002 - TRANSFER-AMI, 2008 - CARESS, 2008 - CAPITAL AMI, 2005 - PRAGUE-1 (thrombolysis+PTCA), 2000 - NORDISTEMI, 2009 - AIR-PAMI , 2002 - DANAMI-2 , 2003 - PRAGUE-2 , 2003 -
primary ballon angioplasty vs intracoronary streptokinase : O'Neill, 1986 -
immediate systematic ballon angioplastyte vs no immediate angioplasty : TAMI 1 pilot, 1987 - ECSG, 1988 - TAMI-5 (Califf), 1991 - SHOCK (Hochman), 1999 - Ellis, 1994 - Erbel, 1989 - MERLIN (Sutton), 2004 - SWISS-SMASH, 1999 - TIMI 2A, 1988 - Belenkie, 1991 - Topol, 1987 -
systematic ballon angioplasty vs no systematic angioplasty : SWIFT, 1991 - SIAM, 1992 - TIMI 2, 1989 - Guerci, 1987 - Van den Brand, 1991 - TOPS, 1992 - TIMI II-A (defered), 0 - Vermeer, 1999 - TAMI 6, 1992 - Barbash, 1990 -
systematic PCI (+stent) vs no systematic PCI : WEST, 2006 - CAPITAL AMI, 2005 - GRACIA-1, 2004 - SIAM III, 2002 - PRAGUE, 2000 -
zotarolimus ES vs paclitaxel ES : ZEST AMI (vs PES), 2009 -
APSAC vs placebo : AIMS, 1988 - German Multicenter Trial, 1988 - ISAM, 1986 - ISIS-2 (SK), 1988 - Western Washington Intravenous Trial, 1988 - GISSI I, 1986 - EMERAS (all delay), 1993 - ISIS 2 pilot, 1987 - EMERAS (7-12h), 1993 - TAMI 6, 1992 - ASSET, 1988 - LATE, 1993 -
zotarolimus ES vs sirolimus ES : ZEST AMI (vs SES), 2009 -
accelerated t-PA vs streptokinase : GUSTO tPA Hiv, 1993 - TEAM 2, 1991 - ISIS III (SK/APSAC), 1992 - Zijlstra , 1993 - Akhras, 1997 - Zwolle, 1994 - Ribeiro, 1993 - Grinfeld, 1996 - Zijlstra, 1997 - INJECT, 1995 - PRIMI (vs SK), 1989 - COMPASS, 1998 - ISIS III (SK/tPA), 1992 - GISSI II, 1990 - International Study Group, 1990 - Centre Illinois, 1993 - Cherng, 1992 - ECSG, 1985 - PAIMS, 1989 - TIMI-1, 1987 - White, 1989 - GUSTO tPA-SK Hiv, 1993 -
accelerated t-PA vs t-PA : RAAMI, 1992 - TEAM 3, 1992 - PAMI, 1993 - STAR, 1995 - SESAM, 1997 - RAPID 1, 1995 - TAMI 5 (t-PA+uroK vs tPA), 1991 - KAMIT, 1991 -
primary ballon angioplasty vs tenecteplase : TRIANA, 2009 -
primary PCI vs thrombolytic therapy : senior PAMI, 2005 -
saruplase vs urokinase : PRIMI (vs UK), 1989 - TAMI 5 (t-PA vs uroK), 1991 -

acute myocardial infarction, antiarrythmic drugs, all type of patients

Nameki, 2004 - IM lidocaine (without infusion) vs control : Koster and Dunning, 1985 - Bennett, 1970 - Pitt, 1971 - Darby, 1972 - Wu, 1992 - Zhu, 2002 - ISIS-4, 1995 -
IM lidocaine (without infusion) vs placebo : Sandlar, 0 - Singh and Kocot, 1976 - Lie (IM), 1978 - Dunn, 1985 - Kostuk and Beanlands, 0 - Baker, 1971 - Chopra, 1971 - O, 0 - Lie (IV), 1974 - Wyse, 1988 - Woods, 1992 - Abraham, 1987 - MAGIC, 2000 - Bhargava, 1995 - Ceremuzynski, 1989 - Chen, 1991 - Feldstedt, 1991 - Gyamlani, 2000 - Ising, 1990 - Morton, 1984 - Nakashima, 2004 - Parikka, 1990 - Raghu, 1999 - Rasmussen, 1986 - Santoro, 2000 - Shechter, 1990 - Shechter, 1991 - Shechter, 1995 - Singh, 1990 - Smith, 1986 - Thogersen, 1995 - Urek, 1996 -

acute myocardial infarction, Late revascularisation, late reperfusion

late PTCA vs no PTCA : TOMIIS, 1994 - Horie et al, 1998 - TOAT, 2002 - DECOPI, 2004 - Silva et al, 2005 - OAT, 2006 - TOSCA-2, 2006 -
streptokinase vs placebo : EMERAS (7-12h), 1993 - LATE, 1993 - TAMI 6, 1992 -

acute myocardial infarction, myocardial revascularization, failed fibrinolysis (rescue revascularisation)

repeat fibrinolysis vs no repeat fibrinolysis : REACT (repeat fibrinolysis), 2005 - Sarullo, 2000 - Mounsey, 1995 -
rescue PTCA vs no rescue PTCA : REACT (rescue PCI), 2005 - MERLIN, 2004 - RESCUE II, 2000 - RESCUE, 1994 - Vermeer, 1999 - Belenkie, 1992 -

acute myocardial infarction, calcium channel blockers, acute short term and post MI studies

Machecourt, 1986 - Tiapamil vs control : Eichler, 1985 - Bussman, 1984 -
diltiazem vs placebo : Gibson, 1986 - MDPIT, 1988 - Zannad, 1988 - DAVIT I, 1984 - Crea, 1985 - DAVIT II, 1990 - CRIS, 1996 - Danish study, 1984 -

acute myocardial infarction, calcium channel blockers, acute (short term) treatment

Machecourt, 1986 - Tiapamil vs control : Eichler, 1985 - Bussman, 1984 -
diltiazem vs placebo : Gibson, 1986 - Zannad, 1988 - Crea, 1985 -

acute myocardial infarction, calcium channel blockers, long term studies

diltiazem vs placebo : MDPIT, 1988 - DAVIT I, 1984 - DAVIT II, 1990 - CRIS, 1996 - Danish study, 1984 -

acute myocardial infarction, nitrates, all type of patients

isosorbide dinitrate vs placebo : Hildebrandt, 1992 - Fitzgerald, 1990 - ISIS-4, 1995 - Hargreaves, 1992 -

acute myocardial infarction, angiotensin-Converting Enzyme Inhibitors, systematic early treatment (with or without sign of HF)

irbesartan vs control : GLOBAL, -
captopril vs placebo : ISIS-4, 1995 - CCS-1, 1995 - French, 1999 - CATS, 1996 - ECCE, 1997 - Sharpe, 1991 - Ray, 1993 - Nabel, 1991 - Bussmann, 1992 - Di Pasquale, 1994 - Di Pasquale, 1997 - Galcera, 1993 - Hargreaves, 1992 - PRACTICAL (captopril), 1994 - CONSENSUS 2, 1992 - Schulman, 1995 - Wagner, 2002 -

acute myocardial infarction, angiotensin-Converting Enzyme Inhibitors, patients with or without HF

irbesartan vs control : GLOBAL, -
captopril vs placebo : ISIS-4, 1995 - CCS-1, 1995 - SAVE, 1992 - Pfeffer, 1988 - Sogaard, 1994 - Sharpe, 1988 - Mortarino, 1990 - French, 1999 - CATS, 1996 - ECCE, 1997 - Sharpe, 1991 - Ray, 1993 - Nabel, 1991 - Bussmann, 1992 - Di Pasquale, 1994 - Di Pasquale, 1997 - Galcera, 1993 - Hargreaves, 1992 - PRACTICAL (captopril), 1994 - CONSENSUS 2, 1992 - Schulman, 1995 - AIRE, 1993 - Wagner, 2002 - TRACE, 1995 -

acute myocardial infarction, angiotensin-Converting Enzyme Inhibitors, patients with left ventricular dysfunction after MI

captopril vs placebo : SAVE, 1992 - Pfeffer, 1988 - Sogaard, 1994 - Sharpe, 1988 - Mortarino, 1990 - AIRE, 1993 - TRACE, 1995 -

acute myocardial infarction, cholesterol lowering intervention, all type of patients

atorvastatin high dose vs pravastatin : PROVE-IT, 2004 -

acute myocardial infarction, anticoagulant, all type of patients

acute myocardial infarction, PCI, all type of patients

primary ballon angioplasty vs accelerated t-PA : Ribichini, 1996 - Garcia, 1997 - GUSTO 2B, 1997 - DANAMI-2, 1997 - C-PORT, 2002 - STAT, 2001 -
facilitated stenting vs alteplase : STOPAMI 1, 2000 -
primary stenting vs ballon angioplasty : Jaksch, 1998 - GRAMI (Rodriguez), 1998 - Zwolle 5 (Suryapranata), 1998 - stent-PAMI (Grines), 1999 - PASTA (Saito), 1999 - PRISAM (Kawashima), 1999 - STENTIM-2 (Maillard), 2000 - PSSAAMI (Scheller), 2001 - FRESCO, 1998 - CADILLAC abciximab., 2002 - CADILLAC (no abciximab), 2002 - ZWOLLE 6, 2005 - STOPAMI 3, 2004 -
paclitaxel ES vs bare-metal stent : PASSION, 2006 - HAAMU-STENT, 2006 - HORIZONS-AMI Stent, 2008 -
primary ballon angioplasty vs duteplase : DeWood, 1989 - Gibbons, 1993 -
primary angioplasty vs immediate thrombolysis : MAASTRICHT (Vermeer), 1999 - PRAGUE-1, 2000 - AIR-PAMI, 2002 - CAPTIM, 2002 - DANAMI-2, 2003 - PRAGUE-2, 2003 - STOPAMI 2, 2002 - PRAGUE-1 (thrombolysis+PTCA), 2000 - NORDISTEMI, 2009 - TRANSFER-AMI, 2008 - CARESS, 2008 - CAPITAL AMI, 2005 - AIR-PAMI , 2002 - DANAMI-2 , 2003 - PRAGUE-2 , 2003 -
primary ballon angioplasty vs intracoronary streptokinase : O'Neill, 1986 -
immediate systematic ballon angioplastyte vs no immediate angioplasty : Belenkie, 1991 - Topol, 1987 - TAMI 1 pilot, 1987 - ECSG, 1988 - TAMI-5 (Califf), 1991 - Ellis, 1994 - Erbel, 1989 - MERLIN (Sutton), 2004 - SWISS-SMASH, 1999 - TIMI 2A, 1988 -
systematic ballon angioplasty vs no systematic angioplasty : TAMI 6, 1992 - Barbash, 1990 - SWIFT, 1991 - SIAM, 1992 - TIMI 2, 1989 - Guerci, 1987 - Van den Brand, 1991 - TOPS, 1992 - TIMI II-A (defered), 0 - Vermeer, 1999 -
systematic PCI (+stent) vs no systematic PCI : WEST, 2006 - CAPITAL AMI, 2005 - GRACIA-1, 2004 - SIAM III, 2002 - PRAGUE, 2000 -
zotarolimus ES vs paclitaxel ES : ZEST AMI (vs PES), 2009 -
zotarolimus ES vs sirolimus ES : ZEST AMI (vs SES), 2009 -
primary ballon angioplasty vs streptokinase : Zwolle, 1994 - Ribeiro, 1993 - Grinfeld, 1996 - Zijlstra, 1997 - Zijlstra , 1993 - Akhras, 1997 -
primary ballon angioplasty vs t-PA : PAMI, 1993 -
primary ballon angioplasty vs tenecteplase : TRIANA, 2009 -
primary PCI vs thrombolytic therapy : senior PAMI, 2005 -

acute myocardial infarction, myocardial revascularization, patients in cardiogenic shock

immediate systematic ballon angioplastyte vs no immediate angioplasty : SHOCK (Hochman), 1999 - SWISS-SMASH, 1999 -

acute myocardial infarction, myocardial revascularization, >6h from onset of symptoms

acute myocardial infarction, angiotensin-receptor blockers, all type of patients

Valsartan+ACE inhibitor vs ACE inhibitor only : VALIANT (valsartan+capropril), 2003 -
Losartan vs Captopril : OPTIMAAL, 2002 - VALIANT (valsartan alone), 2003 -

acute myocardial infarction, myocardial revascularization, patient ineligible for thrombolysis

primary stenting vs ballon angioplasty : STOPAMI 3, 2004 -

acute myocardial infarction, PCI, patient ineligible for thrombolysis

primary stenting vs ballon angioplasty : STOPAMI 3, 2004 -

acute myocardial infarction, myocardial revascularization, patients with inducible post MI ischemia

invasive strategy vs concervative strategy : DANAMI, 1997 -

acute myocardial infarction, PCI, patients with inducible post MI ischemia

invasive strategy vs concervative strategy : DANAMI, 1997 -

acute myocardial infarction, PCI, failed fibrinolysis (rescue PCI)

acute myocardial infarction, fibrinolysis, all type of patients

duteplase 1, 1993 - ASSENT-1, 1999 - Mathey, 1985 - bolus t-PA vs accelerated t-PA : COBALT, 1997 - InTIME-II, 2000 - inTIME 1, 1998 - GUSTO III, 1997 - RAPID-2, 1996 - ASSENT-2, 1999 - TIMI 10B, 1998 -
accelerated t-PA vs APSAC : TAPS, 1992 - TIMI 4, 1994 - Bassand, 1991 -
APSAC vs control : APSIM, 1989 - USIM, 1991 -
t-PA vs duteplase : duteplase 2, 1993 - duteplase 3, 1993 -
APSAC vs placebo : AIMS, 1988 - German Multicenter Trial, 1988 - GISSI I, 1986 - EMERAS (all delay), 1993 - ISIS 2 pilot, 1987 - EMERAS (7-12h), 1993 - ISAM, 1986 - ISIS-2 (SK), 1988 - Western Washington Intravenous Trial, 1988 - LATE, 1993 - TAMI 6, 1992 - ASSET, 1988 -
accelerated t-PA vs streptokinase : GUSTO tPA Hiv, 1993 - TEAM 2, 1991 - ISIS III (SK/APSAC), 1992 - INJECT, 1995 - COMPASS, 1998 - PRIMI (vs SK), 1989 - ISIS III (SK/tPA), 1992 - Centre Illinois, 1993 - Cherng, 1992 - ECSG, 1985 - PAIMS, 1989 - TIMI-1, 1987 - White, 1989 - GISSI II, 1990 - International Study Group, 1990 - GUSTO tPA-SK Hiv, 1993 -
accelerated t-PA vs t-PA : RAAMI, 1992 - TEAM 3, 1992 - STAR, 1995 - SESAM, 1997 - RAPID 1, 1995 - TAMI 5 (t-PA+uroK vs tPA), 1991 - KAMIT, 1991 -
saruplase vs urokinase : PRIMI (vs UK), 1989 - TAMI 5 (t-PA vs uroK), 1991 -

acute myocardial infarction, fibrinolysis, >6h from onset of symptoms

t-PA vs placebo : LATE, 1993 -

acute myocardial infarction, complement inhibition, all type of patients

pexelizumab vs placebo : APEX-AMI, 2007 - COMMA, 2003 - COMPLY, 2003 -

acute myocardial infarction, complement inhibition, patient undergoing primary angioplasty

pexelizumab vs placebo : APEX-AMI, 2007 -

acute myocardial infarction, heparin (UFH or LMWH), patients eligible to receive fibrinolytic therapy

Enoxaparin vs UFH : HART II, 2001 - Baird, 2002 -

acute myocardial infarction, cell-based therapies , PCI

autologous bone marrow stem cells vs control : ASTAMi (Lunde), 2006 - Meluzin LD, 2006 - Meluzin HD, 2006 - BOOSt (Meyer), 2004 - Penicka, 2007 - Ruan, 2005 - BALANCE, 2009 - MAGIC (cell infusion ), 2004 - Suarez de Lezo (cell), 2007 - TCT-STAMI (Ge), 2006 - Huang, 2006 - MAGIC Cell-3-DES (Kang), 2006 - Karpov, 2005 - Li, 2007 - CADUCEUS, -
autologous bone marrow stem cells vs placebo : REPAIR-AMI (Schachinger), 2006 - Janssens, 2006 - NCT00975234, - MARVEL, -

acute myocardial infarction, PCI, Elderly patients

primary ballon angioplasty vs tenecteplase : TRIANA, 2009 -
primary PCI vs thrombolytic therapy : senior PAMI, 2005 -

acute myocardial infarction, myocardial revascularization, Elderly patients

primary ballon angioplasty vs tenecteplase : TRIANA, 2009 -
primary PCI vs thrombolytic therapy : senior PAMI, 2005 -

acute myocardial infarction, thrombectomy, all type of patients

Angioguard vs conventional PCI : DIPLOMATE, 2004 - Wang, 2003 - AiMI, 2006 - Florence, 2004 - Tahk, 2008 - MICADO, 2007 - Ochala, 2007 - EMERALD, 2005 - ASPARAGUS, 2008 - Nanasato, 2004 - VAMPIRE, 2004 -

acute myocardial infarction, percutaneous left ventricular assist devices , cardiogenic shock

Impella LP2.5 vs intra-aortic balloon pump : Seyfarth, 2008 - Thiele, 2005 - Burkhoff, 2006 -

acute myocardial infarction, ICD , all type of patients

early implantation of ICD after MI vs control : IRIS, 2009 -

acute myocardial infarction, antiplatelets drug, all type of patients

aspirin vs control : Huddinge, 1988 - Frankfurt, 1976 - Jones, 1987 - Dutch sulphinpyrazone, 1986 -
aspirin vs placebo : Dutch-aspirin, 1990 - ISIS-pilot, 1987 - ISIS-2, 1988 - APRICOT, 1993 - Wilcox, 1980 - Louvain sulphinpyrazone, 1983 -

acute myocardial infarction, oxygen therapy, all type of patients

hyperbaric oxygen vs control : Sharifi, 2004 - Swift, 1992 - Thurston, 1973 - Hot MI, 1997 - HOT MI pilot, 1997 - Rawles, 1976 - Ukholkina, 2005 - Wilson, 1997 - AMIHOT II , 2000 - AMIHOT, 2007 -

aortic stenosis

aortic stenosis, cholesterol lowering intervention, all type of patients

atorvastatin vs placebo : SALTIRE, 2005 - SEAS, 2008 - ASTRONOMER, 2010 -

atrial fibrillation

atrial fibrillation, antithrombotics, primary prevention of thromboembolic events

atrial fibrillation, rythm control, all type of patients

electrical cardioversion vs rate control : Hot cafe, 2004 - RACE, 2002 - STAF, 2003 - J-RHYTHM, 0 - AFFIRM, 2002 - PIAF, 2000 - AF-CHF, 2002 -

atrial fibrillation, antiarrythmic drugs, maintaining sinus rhythm after cardioversion

dronedarone vs amiodarone : DIONISOS, 2007 -
sotalol vs bisoprolol : Plewan, 2001 -
amiodarone vs class I drugs : AFFIRM Substudy (amiodarone vs class I drugs), 2003 - AFFIRM Substudy (sotalol vs class I drugs), 2003 -
flecainide vs digoxin : Steinbeck (flecainide vs digoxin), 1988 -
amiodarone vs disopyramide : Villani, 1992 -
propafenone vs flecainide : FAPIS, 1996 - Carunchio (sotalol vs flecianide), 1995 -
flecainide vs no treatment : Van Gelder, 1989 -
amiodarone vs placebo : Channer, 2004 - GEFACA, 2001 - Kochiadakis (amiodarone vs placebo), 2000 - SAFE-T (amiodarone vs placebo), 2005 - SMART, 2002 - ASAP, 2003 - Karlson, 1998 - Lloyd (Disopyramide vs placebo), 1984 - EURIDIS, 2007 - ADONIS, 2007 - DAFNE, 2003 - EURIDIS ADONIS (pooled analysis), 2009 - ATHENA, 2009 - Carunchio (flecainide vs placebo), 1995 - Nodari, 2010 - Okishige, 2000 - Bellandi (propafenone vs placebo), 2001 - Dogan, 2004 - Kochiadakis b (propafenone vs placebo), 2004 - RAFT, 2003 - Stroobandt, 1997 - Benditt, 1999 - Singh, 1991 - Bellandi (sotalol vs placebo), 2001 - Carunchio (sotalol vs placebo), 1995 - Kochiadakis (sotalol vs placebo), 2000 - Kochiadakis b (sotalol vs placebo), 2004 - PAFAC (sotalol vs placebo), 2004 - SAFE-T (sotalol vs placebo), 2005 - SOPAT (sotalol vs placebo), 2004 -
amiodarone vs propafenone : Kochiadakis a, 2004 - PRODIS, 1996 - Aliot, 1996 - Kochiadakis b (sotalol vs propafenome), 2004 -
amiodarone vs quinidine : Vitolo, 1981 - Lloyd (Disopyramide vs quinidine), 1984 - Naccarelli, 1996 - Richiardi, 1992 -
amiodarone vs sotalol : AFFIRM Substudy (amiodarone vs sotalol), 2003 - Kochiadakis (amiodarone vs sotalol), 2000 - SAFE-T (amiodarone vs sotalol), 2005 - Reimold, 1993 -

atrial fibrillation, antiarrythmic drugs, rate control

dronedarone vs placebo : ERATO, 2008 -
lenient rate control vs strict rate control : RACE II, 2010 -

atrial fibrillation, catheter ablation , all type of patients

catheter ablation vs control : A4 (Jais), 2008 - Wazni , 2005 - RESOLVE-AF, - MANTRA-PAF, - APAF (Pappone), 2006 - CAFCOAF (Stabile), 2006 - Krittayaphong, 2003 - ThermoCool AF, 2008 - Oral, 2006 - Forleo, 2009 - Lakkireddy, 2006 - Pappone, 2003 - CABANA, -

atrial fibrillation, prevention, patient with history of atrial fibrillation

atorvastatin vs control : Ozaydin, 2006 - Ueng, 2003 - Madrid, 2002 - Tveit, 2004 -
atorvastatin vs placebo : STOP-AF, - Almroth, 2009 - MIRACL (sub-group) (Schwartz), 2004 - Dernellis, 2006 - CAPRAF (Tveit), 2007 - ACTIVE I, 2009 - ANTIPAF, - Brown, - GISSI-AF (Disertori), 2009 -

atrial fibrillation, prevention, patients without history of AF (primary prevention)

losartan vs atenolol : LIFE (AF ancillary study), 2005 -
atorvastatin vs placebo : ARMYDA-3 (AF ancillary study), 2006 - Chello, 2006 - MIRACL (AF ancillary study), 2001 - CHARM (AF ancillary study), 2005 - SOLVD (AF ancillary study), 2003 - GISSI HF (subgroup and ancillary study), 2009 - TRACE (AF ancillary study), 1999 - Val-HeFT (AF ancillary study), 2003 -

atrial fibrillation, embolic protection, all type of patients

PLAATO, - Watchman vs warfarin : PROTECT-AF, -

atrial fibrillation, direct antithrombins, all type of patients

dabigatran 110mg vs warfarin standard dose : RE-LY (110mg), 2009 - PETRO (150mg), 2007 - RE-LY (150mg), 2009 - SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - SPORTIF III , 2003 - SPORTIF V , 2005 -

atrial fibrillation, direct factor Xa inhibitors, all type of patients

apixaban vs aspirin : AVERROES (CV185-048), -
apixaban vs warfarin : ARISTOTLE (CV185-030), - B0661003, - NCT00504556, 0 - ENGAGE-AF TIMI 48, - ROCKET-AF (NCT00403767), 0 - NCT00494871, -

atrial fibrillation, new oral anticoagulant, all type of patients

apixaban vs aspirin : AVERROES (CV185-048), -
apixaban vs warfarin : ARISTOTLE (CV185-030), - B0661003, - ENGAGE-AF TIMI 48, - NCT00504556, 0 - NCT00494871, - ROCKET-AF (NCT00403767), 0 -
dabigatran 110mg vs warfarin standard dose : RE-LY (110mg), 2009 - PETRO (150mg), 2007 - RE-LY (150mg), 2009 - SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - SPORTIF III , 2003 - SPORTIF V , 2005 -

atrial fibrillation, antithrombotics, secondary prevention of thromboembolic events

trifusal+coumadin medium dose vs coumadin standard dose : NASPEAF, 2004 -
aspirin vs placebo : EAFT, 1993 - UK-TIA(high dose), 1991 - UK-TIA(low dose), 1991 - ESPS II, 1996 - EAFT, 1993 - SPINAF, 1992 -
aspirin vs placebo (on top fluidione) : FFAACS , 2001 -
aspirine vs warfarin : EAFT, 1993 - RE-LY 110mg subgroup, 2010 - RE-LY 150mg subgroup, -

atrial fibrillation, rate control, all type of patients

rate control vs electrical cardioversion : Hot cafe (rate vs rythm control), 2004 - RACE (rate vs rythm control), 2002 - STAF (rate vs rythm control), 2003 -
rate control vs pharmacological cardioversion : AFFIRM (rate vs rythm control), 2002 - PIAF (rate vs rythm control), 2000 - AF-CHF (rate vs rythm control), 2002 -
lenient rate control vs strict rate control : RACE II, 2010 -

atrioventricular block or sick sinus syndrome

atrioventricular block or sick sinus syndrome, pacemaker, all type of patients

Physiological’ pacemaker vs VVI,VVIR : CTOPP, 2000 - Mattioli, 1998 -

CABG surgery

CABG surgery, cholesterol lowering intervention, preoperative statins

preoperative simvastatin vs no treatment : Christenson, 1999 -
preoperative atorvastatin vs placebo : Chello et al., 2006 - Patti et al., 2006 -

CABG surgery, antiplatelets drug, all type of patients

clopidogrel+aspirin vs aspirin : CASCADE, 2009 -
aspirin + dypiridamol vs control : Czech, 1986 - Des Moines, 1980 - Pantely, 1979 - Brussels, 1987 - Toronto dipyridamole, 1987 - German sulotroban, 1989 -
aspirin vs placebo : Sydney, 1991 - Hockings, 1993 - McEnany, 1982 - Lorenz, 1984 - GESIC (aspirin), 1990 - Basel, 1989 - Leeds-B, 1985 - Thaulow, 1987 - GESIC (aspirin+dipyridamol), 1990 - Brooks, 1985 - Mayo-A, 1984 - Wadsworth, 1985 - Bridge, - Ekestrom, 1990 - Baur, 1982 - Guiteras, 1989 - VA Co-op CABG, 1988 -

CABG surgery, vein grafts pretreatment, all type of patients

edifoligide pretreatment vs placebo : PREVENT IV, 2005 -

CABG surgery, radial graft, all type of patients

artery grafts vs saphenous vein grafts : CARRPO, 2009 - RAS, - RAPS (Desai), 2004 - RSVP, 2008 - Hayward (Younger), 2008 - Gaudino (radial A), 2005 - VA CABG, 2010 - Gaudino (RITA), 2005 -

cardiac arrest

cardiac arrest, antiarrythmic drugs, out hospital patients

amiodarone vs lidocaine : ALIVE, 2002 -
amiodarone vs placebo : ARREST, 1999 -

cardiac arrest, fibrinolysis, all type of patients

t-PA vs placebo : Abu-Laban, 2002 - TROICA, 2008 - TICA, 2004 -

cardiac arrest, vasopressin, all type of patients

vasopressin vs epinephrine : Lindner, 1997 - Li, 1999 - Lee, 2000 - Stiell, 2001 - Wenzel, 2004 -

cardiac arrest, Public Access Defibrillation , all type of patients

Automatic External Defibrillation vs Cardiopulmonary Resuscitation : HAT, - PAD (Hallstrom), 2004 -

cardiovascular prevention

cardiovascular prevention, cholesterol lowering intervention, patients with LDL elevation and without CHD

cholestyramine vs placebo : LRC, 1984 - WHO clofibrate, 1978 - Cullen, 1974 - AFCAPS/TexCAPS, 1998 - WOSCOPS, 1995 -

cardiovascular prevention, cholesterol lowering intervention, diabetic patients

atorvastatin high dose vs atorvastatin : TNT (sub group), 2006 -
aggressive cholesterol-lowering vs moderate cholesterol-lowering : Post CABG (sub group), 1999 -
atorvastatin vs placebo : ASCOT (diabetics sub group), 2003 - CARDS, 2004 - Deutsche Diabetes Dialyse Studie (4D), 2005 - ASPEN, 2006 - SENDCAP, 1998 - Harrold, 1969 - Hanefeld, 1991 - Emmerich, 2009 - FIELD, 2005 - DAIS, 2001 - LIPS (sub group), 2002 - ALERT (sub group), 2003 - AFCAPS/TexCAPS (sub group), 1998 - PROSPER (sub group), 2002 - LIPID (sub group), 1998 - CARE (sub group), 1998 - WOSCOPS (sub group), 1996 - HPS (sub group), 2002 - 4S (sub group), 1999 -
fenofibrate vs placebo (on top simvastatine) : ACCORD lipid, 2010 - ACCORD lipid (subgroup Eye study), 2010 -
pravastatin high dose vs pravastatin : PROVE IT TIMI 22 (diabetic sub group), 2006 -
pravastatin vs usual care : GISSI P (sub group), 2000 - ALLHAT-LLT (sub group), 2002 -

cardiovascular prevention, cholesterol lowering intervention, elderly

fluvastatin vs placebo : FLARE (subgroup), 1999 - LIPS (subgroup), 2002 - CRISP 20mg, 1994 - PLAC I (sub group), 1995 - REGRESS (subgroup), 1995 - PROSPER, 2002 - CARE (subgroup), 1998 - LIPID (sub group), 2001 - JUPITER (sub group), 2009 - 4S (subgroup), 1997 - HPS (subgroup), 2002 -

cardiovascular prevention, cholesterol lowering intervention, high risk patients with or without LDL cholesterol elevation

ezetimibe + atorvastatin vs atorvastatin : ZETELD, 2010 -
atorvastatin vs placebo : ASCOT, 2003 - PROSPER, 2002 - REGRESS, 1995 - PMSG, 1993 - JUPITER, 2008 - HPS, 2002 -
pravastatin vs usual care : ALLHAT, 2002 -

cardiovascular prevention, cholesterol lowering intervention, patients with prior MI or with CHD

atorvastatin high dose vs atorvastatin : TNT, 2005 -
cholestyramine vs control : STARS (cholestyramine), 1992 - VA drugs, 1968 -
atorvastatin high dose vs lovastatin : Vascular basis, 2005 -
low fat diet vs mediterranean-style diet : Tuttle, 2008 -
partial ileum bypass surgery vs no surgery : POSCH, 1990 -
atorvastatin vs placebo : MIRACL, 2001 - SENDCAP, 1998 - CLAS, 1987 - LCAS, 1997 - Riegger et al., 1999 - FLARE, 1999 - CDP niacin, 1975 - LIPID, 1998 - CARE, 1996 - 4S, 1994 - CIS, 1997 - HARP, 1994 -
atorvastatin high dose vs pravastatin : REVERSAL, 2004 - PROVE-IT, 2004 - SAGE, 2007 -
atorvastatin high dose vs simvastatin : IDEAL, 2005 - SEARCH, 2009 -
atorvastatin vs usual care : GREACE, 2002 - Sahni, 1991 - CLAPT, 1999 - GISSI Prevenzione, 2000 - SCRIP, 1994 -

cardiovascular prevention, antithrombotics, patienst at high risk

aspirin vs no treatment : Primary Prevention Project, 2001 -
aspirin vs placebo : Thrombosis Prevention Trial, 1998 - HOT, 1998 - Thrombosis Prevention trial (Warfarin), 1998 - Thrombosis Prevention trial (W plus A), 1998 -

cardiovascular prevention, omega-3 fatty acids , all type of patients

diet advice vs control : Mate-Jimenez, 1991 - Burr (DART), 1989 - Burr (DART 2), 2003 - Bellamy, 1992 - Dehmer, 1998 - Kaul, 1992 - Eritsland, 1996 - GISSI-P, 1999 - OMEGA, 2009 - Milner, 1989 -
alpha-linolenic acid vs placebo : Natvig, 1968 - ALPHA OMEGA (ALA), 2010 - Veale, 1994 - Maresta, 2002 - Sirtori, 1998 - Hawthorne, 1992 - Lau, 1995 - Nye, 1990 - Singh, 1997 - Skoldstam, 1992 - Thien, 1993 - Bairati, 1992 - Greenfield, 1993 - Lau, 1993 - Nilsen, 2001 - Johansen, 1999 - GISSI HF fatty acid, 2008 - n3-PUFA-HF, - ALPHA OMEGA (EPA DHA), 2010 - Bonnema, 1995 - Sacks (HARP), 1995 - Connor, 1993 - Belluzzi, 1996 - Reis, 1991 -

cardiovascular prevention, omega-3 fatty acids , patients at high risk

diet advice vs control : Burr (DART), 1989 - Burr (DART 2), 2003 - Bellamy, 1992 - Dehmer, 1998 - Kaul, 1992 - Eritsland, 1996 - GISSI-P, 1999 - OMEGA, 2009 - Milner, 1989 -
alpha-linolenic acid vs placebo : Natvig, 1968 - ALPHA OMEGA (ALA), 2010 - Maresta, 2002 - Sirtori, 1998 - Hawthorne, 1992 - Bairati, 1992 - Lau, 1993 - Lau, 1995 - Nye, 1990 - Singh, 1997 - Johansen, 1999 - Nilsen, 2001 - GISSI HF fatty acid, 2008 - n3-PUFA-HF, - ALPHA OMEGA (EPA DHA), 2010 - Bonnema, 1995 - Connor, 1993 - Sacks (HARP), 1995 - Reis, 1991 -

cardiovascular prevention, omega-3 fatty acids , pateints at low risk

diet advice vs control : Mate-Jimenez, 1991 -
Efamol marine vs placebo : Veale, 1994 - Greenfield, 1993 - Skoldstam, 1992 - Thien, 1993 - Belluzzi, 1996 -

cardiovascular prevention, cholesterol lowering intervention, patients with other atherosclerotic localisation

policosanol vs control : Castano, 2001 -
bezafibrate vs placebo : LEADER, 2002 - Begg, 1971 - Acheson, 1972 - VA Neurology Section, 1974 - BCAPS, 2001 - ACAPS, 1994 - CAIUS, 1996 -

cardiovascular prevention, plasma homocysteine lowering intervention, all type of patients

folic acid vs control : FOLARDA (Liem), 2004 - GOES (Liem), 2003 - NORVIT (folic acid + B12) (Bonaa), 2006 - NORVIT (folic acid, B12 and vit B6) (Bonaa), 2006 -
high dose - folic acid, vit B12 and vit B6 vs low dose - folic acid, vit B12 and vit B6 : VISP (Toole), 2004 -
folic acid vs placebo : CHAOS-2, 2002 - CSPPT, - SEARCH, 2007 - WENBIT (folic ac,B12), 2008 - WAFACS, 2008 - HOPE-2 (Lonn), 2006 - VITATOPS, 2010 - SU.FOL.OM3, - FAVORIT, -

cardiovascular prevention, antioxydants, all type of patients

vitamin E vs control : GISSI, 1999 - PPP, 2001 -
acetylcysteine vs placebo : Tepel, 2003 - HPS antioxidant, 2002 - WAVE (Waters), 2002 - POPADAD (antioxydant), 2008 - PHS II beta carotene, 2003 - SUVIMAX, 2005 - HATS, 2001 - MVP, 1997 - ATBC beta carotene, 1994 - CARET beta carotene, 1996 - SCP beta carotene, 1990 - NSCP (Green) beta carotene, 1999 - PHS beta carotene, 1996 - WHS beta carotene, 1999 - WACS beta-caroten, 2007 - WACS vitamin C, 2007 - PHS II vitamin C, 2008 - ATBC vitamin E, 1994 - CHAOS, 1996 - HOPE, 2000 - AREDS, 2001 - Linxian, 1993 - WACS vitamin E, 2007 - PHS II vitamin E, 2008 - SECURE, 2001 - WHS vitamin E, 2005 - ASAP, 2000 - MASI, 2000 -

cardiovascular prevention, antithrombotics, all type of patients

aspirin vs no treatment : British Doctor’s Trial, 1988 - Primary Prevention Project, 2001 -
aspirin vs placebo : Physicians Health Study, 1989 - Thrombosis Prevention Trial, 1998 - HOT, 1998 - Women’s Health Study, 2005 - Thrombosis Prevention trial (Warfarin), 1998 - Thrombosis Prevention trial (W plus A), 1998 -

cardiovascular prevention, cholesterol lowering intervention, patient with related disease

atorvastatin vs placebo : SALTIRE, 2005 - SEAS, 2008 - ALERT, 2003 - PREVEND IT, 2004 - ASTRONOMER, 2010 -

cardiovascular prevention, cholesterol lowering intervention, all chronical situations

atorvastatin vs angioplasty : AVERT, 1999 -
atorvastatin high dose vs atorvastatin : TNT, 2005 - ZETELD, 2010 -
cholestyramine vs control : STARS (cholestyramine), 1992 - VA drugs, 1968 - Más, 1999 - Batista, 1996 - Castano, 2001 - ASTEROID, 0 - Hong, 2005 -
intensive lipid-lowering therapy vs diet : FATS, 1990 -
hypocholéstérolémiants vs diététique : St Thomas, 1983 -
simvastatin vs ezetimibe : Landmesser, 2005 -
atorvastatin high dose vs lovastatin : Vascular basis, 2005 -
low fat diet vs mediterranean-style diet : Tuttle, 2008 -
partial ileum bypass surgery vs no surgery : POSCH, 1990 -
atorvastatin vs placebo : Mohler III, 2003 - CARDS, 2004 - ASCOT, 2003 - MIRACL, 2001 - SPARCL, 2006 - ASPEN, 2006 - Strey, 2005 - SENDCAP, 1998 - BECAIT, 1996 - LEADER, 2002 - BIP, 2000 - LEADER trial, 2000 - Laufs, 2004 - NHLBI (Brensike), 1984 - LRC, 1984 - Harrold, 1969 - Begg, 1971 - Acheson, 1972 - VA Neurology Section, 1974 - Cullen, 1974 - WHO clofibrate, 1978 - Hanefeld, 1991 - CDP Clofibrate, 1975 - Scottish, 1971 - Newcastle, 1971 - Carlson (Stockholm), 1977 - SCOR, 1990 - CLAS, 1987 - CLAS, 1987 - Emmerich, 2009 - FIELD, 2005 - DAIS, 2001 - LIPS, 2002 - ALERT, 2003 - LCAS, 1997 - Riegger et al., 1999 - BCAPS, 2001 - FLARE, 1999 - Schumer W, 1963 - CRISP 20mg, 1994 - ACAPS, 1994 - CCAIT, 1994 - MARS, 1993 - AFCAPS/TexCAPS, 1998 - CRISP 40mg, 1994 - Excel, 1991 - Weintraub, 1994 - CDP niacin, 1975 - Blann, 2001 - REGRESS, 1995 - PMSG, 1993 - CAIUS, 1996 - PROSPER, 2002 - PLAC I, 1995 - PLAC II, 1995 - PACT, 2004 - KAPS, 1995 - LIPID, 1998 - CARE, 1996 - WOSCOPS, 1995 - MEGA, 2006 - GISSI-HF rosuvastatine, 2008 - METEOR, 2007 - JUPITER, 2008 - CORONA, 2007 - Krum, 2007 - CIS, 1997 - Aronow , 2003 - MAAS, 1994 - HPS, 2002 - 4S, 1994 - Node, 2003 - Mondillo, 2003 - HARP, 1994 - Davis, 1975 -
lovastatin vs policosanol : Castano, 2003 -
atorvastatin high dose vs pravastatin : REVERSAL, 2004 - PROVE-IT, 2004 - SAGE, 2007 -
atorvastatin high dose vs simvastatin : IDEAL, 2005 - A to Z, 2004 - SEARCH, 2009 -
atorvastatin vs usual care : GREACE, 2002 - Sahni, 1991 - CLAPT, 1999 - ALLHAT, 2002 - GISSI Prevenzione, 2000 - SCRIP, 1994 -

cardiovascular prevention, cholesterol lowering intervention, post stroke (or TIA)

atorvastatin vs placebo : SPARCL, 2006 - HPS (sub groups), 2004 -

cardiovascular prevention, antiplatelets drug, diabetic patients

aspirin vs no treatment : JPAD, 2008 - PPP (diabetics sub group), 2003 -
aspirin vs placebo : ASCEND (aspirin), 0 - POPADAD aspirin, 2008 - ACCEPT-D, 0 - DAMAD, 1989 - ETDRS, 1992 - PHS (diabetics sub group), 1989 - WHS (diabetics sub group), 2005 - Cocozza, 1995 - Dutch, 1980 -

cardiovascular prevention, antiplatelets drug, all type of patients

clopidogrel + aspirin vs aspirin : CHARISMA, 2006 -
aspirin vs no treatment : British Doctor’s Trial, 1988 - Primary Prevention Project, 2001 -
aspirin vs placebo : Physicians Health Study, 1989 - Thrombosis Prevention Trial, 1998 - HOT, 1998 - Women’s Health Study, 2005 - AAA, 2009 -

cardiovascular prevention, antioxydants, diabetic patients

association vs placebo : POPADAD (antioxydant), 2008 -

cardiovascular prevention, cholesterol lowering intervention, primary prevention

pravastatin vs control : FAST Fukuoka pravastatin, 2002 -
atorvastatin vs placebo : CARDS, 2004 - ASCOT, 2003 - ASPEN, 2006 - Mohler, 2003 - ASPEN (primary prevention sub group), 2006 - ALERT, 2003 - BCAPS, 2001 - HYRIM, 2005 - AFCAPS/TexCAPS, 1998 - ACAPS, 1994 - KAPS, 1995 - WOSCOPS, 1995 - MEGA, 2006 - PMSG, 1993 - CAIUS, 1996 - PHYLLIS, 2004 - PROSPER (primary prevention subgroup), 2002 - JUPITER, 2008 - HPS (primary prevention sub group), 2003 -
pravastatin vs usual care : ALLHAT, 2002 - KLIS, 2000 -

cardiovascular prevention, antiplatelets drug, secondary prevention in patients with intermittent claudication

aspirin vs placebo : Schoop, 1983 - Hess, 1985 - Munich A, 1975 - Munich B, 1975 - CLIPS, 2007 - PACK, 1996 - Walden, 1991 - Thulesius, 1987 - Bounameaux, 1985 - Cameron, 1987 - Clément, 1989 - ADEP, 1993 - Neirotti, 1994 - Coto, 1989 -

cardiovascular prevention, antiplatelets drug, secondary prevention in patients with CAD

dipyridamol+Aspirin vs aspirin : PARIS, 1980 -
dipyridamol vs control : Atlanta (Sbar), 1967 - Becker, 1967 - Wirecki, 1967 -
aspirin vs placebo : CDPA, 1976 - Cardiff I, 1974 - Cardiff II, 1979 - Vogel, 1979 - AMIS, 1980 - GAMIS, 1980 - PARIS, 1980 - JAMIS, 1999 - SAPAT, 1992 - Igloe, 1970 - Zion, 1961 - Kinsella, 1962 - Leiberman, 1964 - Dewar, 1961 - Neumann, 1964 - Foulds, 1960 - PARIS, 1980 - PARIS-II, 1986 -

cardiovascular prevention, lifestyle intervention, all type of patients

Multiple risk factor interventions vs control : HDFP, 1979 - Johns Hopkins, 1983 - MRFIT, 1982 - Meland, 1997 - OXCHECK, 1994 - Oslo, 1981 - WHO Factories, 1982 - Helsinki Businessmen Study, 1985 - CELL, 1995 - Family Heart, 1994 - Göteborg Study, 1986 -
low fat diet vs mediterranean-style diet : Tuttle, 2008 -

cardiovascular prevention, cholesterol lowering intervention, patients with renal insufficiency (on hemodialysis or transplant)

atorvastatin vs placebo : Deutsche Diabetes Dialyse Studie (4D), 2005 - ALERT, 2003 - AURORA, 2009 -

cardiovascular prevention, antiplatelets drug, primary prevention

cardiovascular prevention, niacin, all type of patients

niacin vs control : VA drugs, 1968 -
niacin vs ezetimibe : ARBITER 6-HALTS (niacin vs ezetimibe), 2009 -
colestipol-niacin vs placebo : CLAS, 1987 - CDP niacin, 1975 - AIM-HIGH, - HPS 2-Thrive, - Oxford Niaspan Study, 2009 - ARBITER 2, 2009 - HATS, 2001 -

cardiovascular prevention, ACAT inhibition, all type of patients

pactimibe vs placebo : CAPTIVATE, 2009 - ACTIVATE, 2006 -

cardiovascular prevention, CEPT inhibition, all type of patients

DEFINE, - torcetrapib vs placebo (on top of atorvastatin) : RADIANCE 1, 2007 - ILLUMINATE, 2007 - RADIANCE 2, 2007 - ILLUSTRATE, 2007 -

cardiovascular prevention, antiplatelets drug, patients without established disease

aspirin vs no treatment : British Doctor’s Trial, 1988 - Primary Prevention Project, 2001 - JPAD, 2008 -
aspirin vs placebo : Physicians Health Study, 1989 - Thrombosis Prevention Trial, 1998 - HOT, 1998 - Women’s Health Study, 2005 - POPADAD aspirin, 2008 - AAA, 2009 -

cardiovascular prevention, antioxydants, patients with renal disease

acetylcysteine vs placebo : Tepel, 2003 - SPACE, 2000 - HOPE renal insufficiency subgroup, 2004 -

cardiovascular prevention, antioxydants, primary prevention

vitamin E vs control : PPP, 2001 -
association vs placebo : PHS II beta carotene, 2003 - SUVIMAX, 2005 - ATBC beta carotene, 1994 - CARET beta carotene, 1996 - PHS beta carotene, 1996 - WHS beta carotene, 1999 - PHS II vitamin C, 2008 - ATBC vitamin E, 1994 - AREDS, 2001 - Linxian, 1993 - PHS II vitamin E, 2008 - WHS vitamin E, 2005 -

cardiovascular prevention, antioxydants, secondary prevention

vitamin E vs control : GISSI, 1999 -
association vs placebo : WAVE (Waters), 2002 - HATS, 2001 - MVP, 1997 - HPS antioxidant, 2002 - WACS beta-caroten, 2007 - ATBC 2nd prev subgroup (b carotene), 1998 - WACS vitamin C, 2007 - CHAOS, 1996 - HOPE, 2000 - SPACE, 2000 - WACS vitamin E, 2007 - SECURE, 2001 - HOPE renal insufficiency subgroup, 2004 - ATBC 2nd prev subgroup (vitamin E), 1998 -

cardiovascular prevention, cholesterol lowering intervention, women

statins vs placebo : AFCAPS (women subgroup) , 1998 - ALLHAT (women subgroup) , 2002 - ASCOT (women subgroup) , 2003 - MEGA (women subgroup) , 2006 - HPS (women subgroup) , 2002 - JUPITER (women subgroup) , 2008 -

cardiovascular prevention, antithrombotics, primary prevention

cardiovascular prevention, weight-loss drugs, overweight or obese patients

rimonabant vs placebo : STRADIVARIUS, 2008 - AUDITOR, 0 - CRESCENDO, 2010 - RIO europe 20mg, 2005 - Rio-lipid 20 mg, 2005 - RIO-North America 20 mg, 2006 - RIO europe 5mg, 2005 - taranabant phase 3, 0 -
rimonabant 20mg vs rimonabant 5mg : RIO europe (20 vs 5 mg), 2005 -

cardiovascular prevention, lifestyle intervention, primary prevention

Multiple risk factor interventions vs control : CELL, 1995 - Family Heart, 1994 - Göteborg Study, 1986 - Johns Hopkins, 1983 - MRFIT, 1982 - Meland, 1997 - OXCHECK, 1994 - Oslo, 1981 - WHO Factories, 1982 - Helsinki Businessmen Study, 1985 -

cardiovascular prevention, plasma homocysteine lowering intervention, patients with chronic kidney disease

***Wrone, 2004 - folic acid vs placebo : ***Righetti, 2006 - ***ASFASR, 2006 - ***HOST, 2007 - ***House, 2010 -

cardiovascular prevention, hormonal replacement therapy, all type of patients

combined estrogen and progestogen vs placebo : ERA (estrogen plus medroxyprogesterone), 2000 - WELL-HART (estrogen-progestin), 2003 - Schulman (NHLBI) (estrogen-progestogen), 2002 - WAVE, 2002 - EAGAR, 2006 - HERS, 1998 - EVTET, 2000 - Hall, 1998 - WHI, 2002 - WHISP, 2006 - WISDOM, 2007 - PEPI, 1995 -

cardiovascular prevention, hormonal replacement therapy, primary prevention

combined estrogen and progestogen vs placebo : WHI, 2002 -

cardiovascular prevention, hormonal replacement therapy, secondary prevention

combined estrogen and progestogen vs placebo : WAVE, 2002 - EAGAR, 2006 - HERS, 1998 - EVTET, 2000 - Hall, 1998 - WHISP, 2006 - ERA (estrogen plus medroxyprogesterone), 2000 - WELL-HART (estrogen-progestin), 2003 - Schulman (NHLBI) (estrogen-progestogen), 2002 -

carotid stenosis

carotid stenosis, endarterectomy, asymptomatic patients

carotid endarterectomy vs control : ACAS, 1995 - ACST, 1994 - VA, 1993 -

carotid stenosis, endovascular treatment, all type of stenosis

carotid artery stenting vs surgery : ICSS, 2010 - Link, 0 - CARESS, - SPACE 2, 0 - Leicester (Naylor), 1998 - WALLSTENT (Alberts), 2001 - CAVATAS-CEA, 2001 - Kentucky A (Brooks), 2001 - SPACE, 2000 - EVA-3S (Mas), 2000 - BACASS (Hoffman), 2006 - Kentucky B (Brooks), 2004 - SAPPHIRE (yadav), 2004 - TESCAS-C (Ling), 2006 - ACST-2, 0 - ACT I, 0 - Agostoni, 0 - CREST, 2010 -

carotid stenosis, endarterectomy, symptomatic patients

carotid endarterectomy vs control : ECST, 1998 - NASCET, 1998 - VA309, 1991 -

coronary artery disease

coronary artery disease, myocardial revascularization, all type of patient

A vs B : DEFER-DES, 0 - EK-12006, 0 - Nordic Bifurcation Study, 0 - RESEARCH à effacer, 2004 - ISAR, 2005 -
paclitaxel ES vs ballon angioplasty : ISAR-DESIRE (PES vs PTCA), 2005 -
dactinomycin ES vs bare-metal stent : ACTION, 2004 - FEMH-93005, 0 - TAXUS I, 2003 - TAXUS II, 2003 - TAXUS IV, 2004 - SCORE, 2004 - TAXUS V (all patients), 2005 - TAXUS VI, 2005 - PASSION, 2006 - HAAMU-STENT, 2006 - Stone pooled analysis TAXUS studies, 2007 - BASKET-SAVAGE, 0 - ASPECT, 2003 - ELUTES, 2004 - DELIVER, 2004 - PATENCY, 2002 - ENDEAVOR II, 2006 -
paclitaxel eluting balloon vs brachytherapy : TAXUS V ISR, 2006 -
ballon angioplasty vs CABG : CABRI, 1995 - EAST, 1994 - GABI, 1994 - Lausanne, 1994 - RITA, 1993 - ERACI, 1992 - Toulouse, 1992 - BARI, 1996 - MASS, 1995 - STICH (ventricular reconstruction), 2009 - SYNTAX, 2009 - Loubani, 2003 - Zhao , 2006 -
zotarolimus ES vs everolimus ES : RESOLUTE, 2010 -
ballon angioplasty vs medical treatment : ACME 2 (Folland), 1997 - RITA 2, 1997 - ACIP, 1997 - ACME, 1992 - INSPIRE, 2006 - Sievers, 1993 - SWISSI II, 2007 - MASS, 1995 - Texas, 1977 - Oregon, 1979 - New zealand 1, 1981 - MASS II, 2007 - VA, 1984 - ECSS (European), 1988 - CASS, 1983 - BARI 2D, 2009 - VELETI, 0 -
angioplasty vs MIDCAB : AMIST (Reeves), 2004 -
CoStar stent vs paclitaxel ES : Costar II, 2008 - PEPCAD IV, 0 - PERSEUS Workhorse, 2010 - ZEST (vs PES), 2009 - ENDEAVOR IV, 2009 - ZoMaxx phase 2, 0 - ZoMaxx phase 3, 2007 - ZEST AMI (vs PES), 2009 -
biodegradable-polymer sirolimus stent vs sirolimus ES : ISAR TEST 3 (BP), 2009 - ISAR TEST 2 (vs SES), 2009 - FRE-RACE, 0 - ISAR-TEST-4, 2009 - DIABEDES IV, 0 - ENDEAVOR III, 2006 - PROTECT, 0 - PRISON III, 2007 - ZEST (vs SES), 2009 - ZEST AMI (vs SES), 2009 -
dual sirolimus, probucol ES vs zotarolimus ES : ISAR TEST 2 (vs ZES), 2009 -

coronary artery disease, myocardial revascularization, diabetic patients

paclitaxel ES vs bare-metal stent : TAXUS II (diabetics), 2003 - TAXUS IV (diabetics), 2005 - TAXUS V (diabetics), 2005 - TAXUS VI (diabetics), 2005 - Kirtane (pooled Taxus diabetic patients), 2008 -
CABG or PCI vs medical treatment : BARI 2D, 2009 -
CoStar stent vs paclitaxel ES : COSTAR II diabetic (sub group), 2008 - PEPCAD IV, 0 -
paclitaxel ES vs sirolimus ES : ISAR-test (diabetics), 2006 - DIABEDES IV, 0 -

coronary artery disease, myocardial revascularization, multivessels disease

ballon angioplasty vs CABG : BARI, 1996 - CABRI, 1995 - EAST, 1994 - GABI, 1994 - RITA, 1993 - ERACI, 1992 - Toulouse, 1992 -

coronary artery disease, myocardial revascularization, single vessel disease

ballon angioplasty vs CABG : MASS, 1995 - Lausanne, 1994 -
angioplasty vs MIDCAB : AMIST (Reeves), 2004 -

coronary artery disease, revascularization with drug eluting stent, all type of patients

A vs B : ISAR, 2005 - DEFER-DES, 0 - EK-12006, 0 - Nordic Bifurcation Study, 0 - RESEARCH à effacer, 2004 -
paclitaxel ES vs ballon angioplasty : ISAR-DESIRE (PES vs PTCA), 2005 -
dactinomycin ES vs bare-metal stent : ACTION, 2004 - FEMH-93005, 0 - Erglis, 2007 - HORIZONS-AMI Stent, 2008 - TAXUS I, 2003 - TAXUS II, 2003 - TAXUS IV, 2004 - SCORE, 2004 - TAXUS V (all patients), 2005 - TAXUS VI, 2005 - PASSION, 2006 - HAAMU-STENT, 2006 - Stone pooled analysis TAXUS studies, 2007 - BASKET-SAVAGE, 0 - ASPECT, 2003 - ELUTES, 2004 - DELIVER, 2004 - PATENCY, 2002 - ENDEAVOR II, 2006 -
paclitaxel ES vs CABG : SYNTAX, 2009 -
zotarolimus ES vs everolimus ES : RESOLUTE, 2010 -
paclitaxel ES vs medical treatment : VELETI, 0 -
CoStar stent vs paclitaxel ES : Costar II, 2008 - PEPCAD IV, 0 - PERSEUS Workhorse, 2010 - ZEST AMI (vs PES), 2009 - ZEST (vs PES), 2009 - ENDEAVOR IV, 2009 - ZoMaxx phase 2, 0 - ZoMaxx phase 3, 2007 -
biodegradable-polymer sirolimus stent vs sirolimus ES : ISAR TEST 3 (BP), 2009 - ISAR TEST 2 (vs SES), 2009 - FRE-RACE, 0 - ISAR-TEST-4, 2009 - ZEST (vs SES), 2009 - SORT-OUT-3, 2010 - DIABEDES IV, 0 - ENDEAVOR III, 2006 - PROTECT, 0 - PRISON III, 2007 -
dual sirolimus, probucol ES vs zotarolimus ES : ISAR TEST 2 (vs ZES), 2009 -

coronary artery disease, revascularization with drug eluting stent, diabetic patients

paclitaxel ES vs bare-metal stent : TAXUS II (diabetics), 2003 - TAXUS IV (diabetics), 2005 - TAXUS V (diabetics), 2005 - TAXUS VI (diabetics), 2005 - Kirtane (pooled Taxus diabetic patients), 2008 -
CoStar stent vs paclitaxel ES : COSTAR II diabetic (sub group), 2008 - PEPCAD IV, 0 -
paclitaxel ES vs sirolimus ES : ISAR-test (diabetics), 2006 - DIABEDES IV, 0 -

coronary artery disease, revascularization with drug eluting stent, acute myocardial infarction

paclitaxel ES vs bare-metal stent : PASSION, 2006 - HAAMU-STENT, 2006 - HORIZONS-AMI Stent, 2008 -
zotarolimus ES vs paclitaxel ES : ZEST AMI (vs PES), 2009 -
zotarolimus ES vs sirolimus ES : ZEST AMI (vs SES), 2009 - SORT-OUT-3, 2010 -

coronary artery disease, revascularization with drug eluting stent, long or complex lesion

paclitaxel ES vs bare-metal stent : TAXUS V (all patients), 2005 -
paclitaxel ES vs CABG : SYNTAX, 2009 -

coronary artery disease, revascularization with drug eluting stent, bypass graft lesion

paclitaxel ES vs bare-metal stent : BASKET-SAVAGE, 0 - SOS, 2008 -
paclitaxel ES vs medical treatment : VELETI, 0 -

coronary artery disease, revascularization with drug eluting stent, in stent restenosis

paclitaxel eluting balloon vs brachytherapy : TAXUS V ISR, 2006 -

coronary artery disease, revascularization with drug eluting stent, unprotected left main artery stenosis

paclitaxel ES vs bare-metal stent : Erglis, 2007 -

coronary artery disease, revascularization with drug eluting stent, bifurcation lesion

A vs B : Nordic Bifurcation Study, 0 -
kissing balloon vs no kissing balloon : Nordic-Baltic Bifurcation Study III, 2009 -

coronary artery disease, revascularization with drug eluting stent, unparticular patients

A vs B : ISAR, 2005 - DEFER-DES, 0 - EK-12006, 0 - RESEARCH à effacer, 2004 -
dactinomycin ES vs bare-metal stent : ACTION, 2004 - FEMH-93005, 0 - TAXUS I, 2003 - TAXUS II, 2003 - TAXUS IV, 2004 - SCORE, 2004 - Stone pooled analysis TAXUS studies, 2007 - ASPECT, 2003 - ELUTES, 2004 - DELIVER, 2004 - PATENCY, 2002 - ENDEAVOR II, 2006 -
zotarolimus ES vs everolimus ES : RESOLUTE, 2010 -
CoStar stent vs paclitaxel ES : Costar II, 2008 - PERSEUS Workhorse, 2010 - ZEST (vs PES), 2009 - ENDEAVOR IV, 2009 - ZoMaxx phase 2, 0 - ZoMaxx phase 3, 2007 -
paclitaxel ES vs sirolimus ES : FRE-RACE, 0 - ISAR-TEST-4, 2009 - ENDEAVOR III, 2006 - PROTECT, 0 - ZEST (vs SES), 2009 -

coronary artery disease, revascularization with drug eluting stent, total occlusion

zotarolimus ES vs sirolimus ES : PRISON III, 2007 -

coronary artery disease, transmyocardial revacularization, all type of patients

TMR+CABG vs CABG : Loubani, 2003 - Zhao , 2006 -

coronary artery disease, cell-based therapies , all type of patients

VEGF gene transfer vs control : REVASC, 2006 -
fibroblast growth factor vs placebo : FIRST, 2002 - AGENT-1, 2002 - AGENT-2, 2003 - AGENT-3, 0 - AGENT-4, 0 - AWARE, 0 - AGENT 3 and 4 pooled, 0 - Seiler, - EUROINJECT-ONE, 2005 - NCT00090714, - Kumar, - Genzyme SMC00202, - VIVA, 2003 -

coronary artery disease, anti-anginal drugs, all type of patients

ranolazine 1000mg vs placebo : MARIZA, 2004 - RAN080, 2005 -
ranolazine 1000mg vs placebo (on top standard treatment) : CARISA 1000mg, 2004 -
ranolazine 1000mg + amlodipine vs placebo + amlodipine : ERICA, 2006 -

coronary artery disease, anti-anginal drugs, hemodialysis patients

nicorandil vs control : Nishimura, 2009 -

coronary artery disease, death and events prevention, all type of patients

diabetes

diabetes, antidiabetic drugs, type 2 diabetes (NIDD)

49653/079 , - 49653/080 , - 49653/082 , - 49653/085 , - 49653/095 , - 49653/097 , - 49653/125 , - 49653/127 , - 49653/128 , - 49653/134 , - 49653/135 , - 49653/136 , - 49653/145 , - 49653/147 , - 49653/162 , - 49653/234 , - 49653/330 , - 49653/331 , - 49653/137 , - SB-712753/002 , - SB-712753/003 , - SB-712753/007 , - SB-712753/009 , - 49653/132 , - AVA100193 , - 49653/011 , - 49653/020 , - 49653/024 , - 49653/093 , - 49653/094 , - 100684 , - 49653/143 , - 49653/211 , - 49653/284 , - 712753/008 , - AVM100264 , - BRL 49653C/185 , - BRL 49653/334 , - BRL 49653/347 , - 49653/015 , - rosiglitazone vs control : Wang, 2005 -
repaglinide (add on met) vs control (add on met) : Moses, 1999 -
nateglinide (add on met) vs gliclazide (add on met) : Ristic, 2006 -
pioglitazone vs glimepiride : PERISCOPE, 2008 -
rosiglitazone vs glipizide : APPROACH, 2008 -
Pioglitazone vs Metformin : EC404, -
Pioglitazone + sulfonylurea vs Metformin + sulfonylurea : EC409, -
nateglinide vs placebo : Marre, 2002 -
pioglitazone vs Placebo : PROactive, 2005 - PNFP-026, - PNFP-012, - PNFP-001, -
rosiglitazone pioglitazone vs placebo : TIDE, -
Pioglitazone + insulin vs Placebo + insulin : PNFP-014, - OPI-502, -
Pioglitazone + metformin vs Placebo +metformin : PNFP-027, -
Pioglitazone vs Rosiglitazone : GLAI, -
pioglitazone vs standard glucose-lowering drugs : PPAR, - ADOPT, 2006 - RECORD, 2009 -
Pioglitazone vs Sulfonylurea : OPI-504, - EC405, - OPI-501, - OPI-520, - OPI-506, 0 - PNFP-010, -
Pioglitazone + metformin vs Sulfonylurea + metformin : EC410, -

diabetes, anti hypertensive agent, type1 and 2 diabetic patients with hypertension

diabetes, cholesterol lowering intervention, diabetic patients with or withour hypercholesterolemia

atorvastatin high dose vs atorvastatin : TNT (sub group), 2006 -
aggressive cholesterol-lowering vs moderate cholesterol-lowering : Post CABG (sub group), 1999 -
atorvastatin vs placebo : ASPEN, 2006 - ASCOT (diabetics sub group), 2003 - FIELD, 2005 - LIPS (sub group), 2002 - ALERT (sub group), 2003 - AFCAPS/TexCAPS (sub group), 1998 - PROSPER (sub group), 2002 - LIPID (sub group), 1998 - CARE (sub group), 1998 - WOSCOPS (sub group), 1996 - 4S (sub group), 1999 - HPS (sub group), 2002 -
fenofibrate vs placebo (on top simvastatine) : ACCORD lipid, 2010 - ACCORD lipid (subgroup Eye study), 2010 -
pravastatin high dose vs pravastatin : PROVE IT TIMI 22 (diabetic sub group), 2006 -
pravastatin vs usual care : GISSI P (sub group), 2000 - ALLHAT-LLT (sub group), 2002 -

diabetes, antiplatelets drug, patients without cardiovascular disease

diabetes, antioxydants, all type of patients

association vs placebo : POPADAD (antioxydant), 2008 -

diabetes, screening for CAD , all type of patients

screening for CAD vs no screening : DIAD, 2009 - DYNAMIT, -

diabetes, glitazone, all type of patients

49653/079 , - 49653/080 , - 49653/082 , - 49653/085 , - 49653/095 , - 49653/097 , - 49653/125 , - 49653/127 , - 49653/128 , - 49653/134 , - 49653/135 , - 49653/136 , - 49653/145 , - 49653/147 , - 49653/162 , - 49653/234 , - 49653/330 , - 49653/331 , - 49653/137 , - SB-712753/002 , - SB-712753/003 , - SB-712753/007 , - SB-712753/009 , - 49653/132 , - AVA100193 , - 49653/011 , - 49653/020 , - 49653/024 , - 49653/093 , - 49653/094 , - 100684 , - 49653/143 , - 49653/211 , - 49653/284 , - 712753/008 , - AVM100264 , - BRL 49653C/185 , - BRL 49653/334 , - BRL 49653/347 , - 49653/015 , - rosiglitazone vs control : Wang, 2005 -
pioglitazone vs glimepiride : PERISCOPE, 2008 -
rosiglitazone vs glipizide : APPROACH, 2008 -
Pioglitazone vs Metformin : EC404, -
Pioglitazone + sulfonylurea vs Metformin + sulfonylurea : EC409, -
pioglitazone vs Placebo : PROactive, 2005 - PNFP-026, - PNFP-012, - PNFP-001, -
rosiglitazone pioglitazone vs placebo : TIDE, -
Pioglitazone + insulin vs Placebo + insulin : PNFP-014, - OPI-502, -
Pioglitazone + metformin vs Placebo +metformin : PNFP-027, -
Pioglitazone vs Rosiglitazone : GLAI, -
pioglitazone vs standard glucose-lowering drugs : PPAR, - ADOPT, 2006 - RECORD, 2009 -
Pioglitazone vs Sulfonylurea : OPI-504, - EC405, - OPI-501, - OPI-520, - OPI-506, 0 - PNFP-010, -
Pioglitazone + metformin vs Sulfonylurea + metformin : EC410, -

diabetes, prevention, all type of patients

AHA 2 diet vs AHA 1 diet : Liao, 2002 -
jiangtang bushen recipe vs control : Fan, 2004 - US-DDP (lifestyle) (Knowler), 2002 - Fang, 2004 - Keen, 1982 - Pan, 1997 - DPS (Lindström), 2003 - Kosaka, 2005 - Tao, 2004 - JDPP (Sakane), 2005 - IDDP (Ramachandran), 2006 - Jarret, 1979 -
acarbose vs placebo : STOP-NIDDM (Chiasson), 2002 - Pan, 2003 - NAVIGATOR nateglinide, 2010 - Heymsfield, 2000 - XENDOS (Chiasson), 2002 - DREAM ramipril, 2006 - DREAM rosiglitazone, 2006 - CANOE, 2010 - TRIPOD (Buchanan), 2002 - US DDP troglitazone (Knowler), 2005 - NAVIGATOR valsartan, 2010 -
intensive dietary advice vs routine dietary advice : Wein, 1999 -

diabetes, antiplatelets drug, all type of patients

aspirin vs no treatment : PPP (diabetics sub group), 2003 - JPAD, 2008 -
aspirin vs placebo : PHS (diabetics sub group), 1989 - WHS (diabetics sub group), 2005 - ASCEND (aspirin), 0 - POPADAD aspirin, 2008 - ACCEPT-D, 0 - DAMAD, 1989 - ETDRS, 1992 - Cocozza, 1995 - Dutch, 1980 -

diabetes, glitazone, patients with cardiovascular disease

rosiglitazone vs control : Wang, 2005 -
pioglitazone vs glimepiride : PERISCOPE, 2008 -
rosiglitazone vs glipizide : APPROACH, 2008 -
pioglitazone vs Placebo : PROactive, 2005 -
rosiglitazone pioglitazone vs placebo : TIDE, -
pioglitazone vs standard glucose-lowering drugs : PPAR, -
Pioglitazone vs Sulfonylurea : OPI-504, - OPI-520, -

diabetes, insulin sensitizer, all type of patients

49653/234 , - 49653/330 , - 49653/331 , - 49653/137 , - SB-712753/002 , - SB-712753/003 , - SB-712753/007 , - SB-712753/009 , - 49653/132 , - AVA100193 , - 49653/011 , - 49653/020 , - 49653/024 , - 49653/093 , - 49653/094 , - 100684 , - 49653/143 , - 49653/211 , - 49653/284 , - 712753/008 , - AVM100264 , - BRL 49653C/185 , -